Dormancy and reactivation of lung cancer cells following cisplatin treatment has also been shown to be dependent on a Sox2/Nanog regulated mechanism relying on sequential cis and trans ephrin type-B receptor 1 (EphB1)-mediated signaling (146). Here, EPHB1 is linked to lung carcinoma.